AGI's pathology and histology platforms provide the detailed tissue-level insight necessary to evaluate safety, efficacy, and systemic responses in preclinical development. Gross necropsy identifies macroscopic abnormalities, while histological scoring characterizes cellular-level changes including inflammation, fibrosis, necrosis, or regeneration. Specialized techniques such as immunohistochemistry and in situ hybridization allow precise localization of therapeutic effects, including expression patterns, immune infiltration, or off-target impacts. Clinical pathology services—including hematology, serum chemistry, coagulation testing, and urinalysis—deliver systemic readouts that correlate functional outcomes with tissue-level findings. These datasets are integrated with imaging and biomarker analyses to create a multiparametric evaluation framework that enhances both interpretability and regulatory alignment.

 

Comprehensive pathology services not only identify safety liabilities but also provide mechanistic evidence to support therapeutic efficacy, ensuring that data packages address both sides of the translational equation. All analyses are performed by experienced veterinary pathologists under validated GLP standards, ensuring reproducibility and global regulatory acceptance. By delivering rigorously generated, fully contextualized tissue-to-system datasets, our pathology services form the foundation for safe and effective drug development programs.